Progenra Revenue and Competitors

Ubiquitin-based drug discovery is at the exciting initial stage - much like that of kinases and phosphatases fifteen years ago. Enzymes such as deubiquitylating enzymes (DUBs) and ubiquitin ligases, like phosphatases and kinases, play key roles in the control of cellular signal transduction pathways. Progenra is committed to discovering and developing high value novel therapeutic medicines based on ubiquitin and ubiquitin-like protein pathways and has established an early stage product portfolio that addresses major unmet medical needs in cancer, inflammation, metabolic diseases, pathogen infection, muscle wasting, and neurodegenerative disease. Progenra's world-class technology, a unique target and drug discovery platform, is being utilized to exploit the role of ubiquitin in pathologies with the goal of developing drugs targeting the ubiquitin-proteasome pathway. The drug discovery platform is complemented by internal biochemical, biological target validation programs and medicinal chemistry/lead optimization.